Histacross L 10mg Tablet contains Levocetirizine, a third-generation non-sedative antihistamine indicated for the relief of symptoms associated with allergic conditions such as allergic rhinitis, chronic idiopathic urticaria, and other histamine-mediated allergic disorders. Levocetirizine selectively inhibits peripheral H1 receptors, thereby preventing the action of endogenous histamine, which is responsible for the symptoms of allergy including sneezing, nasal congestion, rhinorrhea, and pruritus. The 10mg dosage provides effective symptom control with a favorable safety profile, minimizing sedation and anticholinergic side effects commonly seen with first-generation antihistamines. Histacross L is rapidly absorbed following oral administration, with peak plasma concentrations achieved within one hour, and it exhibits a prolonged duration of action, allowing once-daily dosing for improved patient compliance. It is metabolized minimally by the liver and primarily excreted unchanged via the kidneys; therefore, dose adjustments may be necessary in patients with renal impairment. Contraindications include hypersensitivity to Levocetirizine or any excipients. Use with caution in patients with severe renal impairment. Common adverse effects include headache, dry mouth, and fatigue, which are generally mild and transient. Histacross L 10mg Tablet should be used under medical supervision, adhering to prescribed dosages to ensure optimal therapeutic outcomes.